TherapeuticsMD (NASDAQ:TXMD) posted its quarterly earnings results on Monday. The company reported ($0.06) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.06), AR Network reports. During the same quarter last year, the company posted ($0.06) earnings per share. TherapeuticsMD Inc. (NYSEMKT:TXMD) shares after opening at $3.93 moved to $3.95 on last trade day and at the end of the day closed at $3.65. Company price to sales ratio in past twelve months was calculated as 60.18 and price to cash ratio as 9.77. TherapeuticsMD Inc. (NYSEMKT:TXMD) showed a negative weekly performance of -9.20%.
NanoViricides, Inc. (NYSEMKT:NNVC) reported that it has designed and synthesized novel nanoviricides® drug candidates in quantities sufficient for testing in animals infected with the MERS Corona Virus. NanoViricides Inc. (NYSEMKT:NNVC) shares advanced 8.25% in last trading session and ended the day on $3.41. NNVC return on equity ratio is recorded as -138.70% and its return on assets is -67.60%. NanoViricides Inc. (NYSEMKT:NNVC) yearly performance is 77.60%.
KYTHERA Biopharmaceuticals (NASDAQ:KYTH) Director Nathaniel David unloaded 1,200 shares of the company’s stock on the open market in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $32.60, for a total value of $39,120.00. Following the completion of the sale, the director now directly owns 496,085 shares in the company, valued at approximately $16,172,371. Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) shares moved down -6.87% in last trading session and was closed at $31.60, while trading in range of $31.22 – $34.07. Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) year to date (YTD) performance is -15.39%.
On April 14, 2014, Retrophin, Inc. (NASDAQ:RTRX) issued a press release updating earnings guidance for 2014 and 2015 and providing an update on the development of certain of the Registrant’s product candidates. Retrophin Inc. (NASDAQ:RTRX) weekly performance is -4.08%. On last trading day company shares ended up $12.70. Retrophin Inc. (NASDAQ:RTRX) distance from 50-day simple moving average (SMA50) is -27.12%. Analysts mean target price for the company is $51.00.